The Plastic Surgery Foundation
Log In Donate Now

Grants We Funded

Grant applicants for the 2023 cycle requested a total of nearly $4 million dollars. The PSF Study Section Subcommittees of Basic & Translational Research and Clinical Research evaluated nearly 140 grant applications on the following topics:

The PSF awarded research grants totaling over $1 million dollars to support nearly 30 plastic surgery research proposals.

ASPS/PSF leadership is committed to continuing to provide high levels of investigator-initiated research support to ensure that plastic surgeons have the needed research resources to be pioneers and innovators in advancing the practice of medicine.

Research Abstracts

Search The PSF database to have easy access to full-text grant abstracts from past PSF-funded research projects 2003 to present. All abstracts are the work of the Principal Investigators and were retrieved from their PSF grant applications. Several different filters may be applied to locate abstracts specific to a particular focus area or PSF funding mechanism.

Study of the Relationship Between Breast Implants and Lymphoma

Principal Investigator
Garry Brody MD


USC/University of Southern California

Funding Mechanism
National Endowment for Plastic Surgery Grant

Focus Area
Breast (Cosmetic / Reconstructive)

A literature review identified a number of cases of an aggressive form of T-cell Anaplastic non Hodgkins Lymphoma associated with breast implants. We know of up to 40 cases reported in the literature, by word of mouth and a few by reasonably reliable hearsay. Despite the very malignant nature seen microscopically and in the laboratory data, the tumor rarely spreads and the patients do well after removal, chemotherapy and/or radiation. All but one are tumor free to date. The implant (both saline and silicone) brand and style when known were all textured by a "lost salt" method. that leaves tiny loops of silicone for fixation. These tumors are very rare (a possible 40 out of many thousands) so far and fortunately seem to be curable.

Our research plan is to accumulate all the information available including as many paraffin blocks as possible. The data will be evaluated epidemiologically to determine risk and the tissue will be evaluated microscopically and by a battery of immunological tests to confirm ALCL. These include: TLBR-1 cells from culture and tissue sections of TLBR-1 tumors grown in SCID for immunohistochemical studies. Cytospin preparations of TLBR-1 cells fixed with 2% parafolmaldehyde (Polysciences, Warrington, Pa) Wright-Gemsa and hematoxilin and eosin stains,, cytospin and paraffin tissue slides will be stained with monoclonal antibodies against human ALK (ALK1 clone, DAKO, Glostrup, Denmark), EMA (clone E29, Cell Marque Corp., Rocklin, Ca), CD30 (clone Ber-H2, DAKO), PAX-5 (clone24, Cell Marque Corp.), and pancytokeratins (clone AE1/3, DAKO) among others. We have received one sample of freshly excised capsule which is growing robustly in tissue culture demonstrating unique characteristics suggesting that this represents a new manifestation of lymphoma.